2Liu L, Zhang Y, Liu G, et al; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens, 2005, 23(12): 2157-2172.
3Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363(9426): 2022-2031.
4Weber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with SystolicHypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press, 2007, 16(1): 13-19.
5Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361(9364): 1149-1158.
6Messerli FH, Staessen JA. Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. Hypertension, 2006, 48(3): 359-361.
